Currently, there are very few guidelines linking the results of pharmacogenetic tests to
specific therapeutic recommendations. Therefore, the Royal Dutch Association for the …

Part I of this article discussed the potential functional importance of genetic mutations and
alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 …

Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

Interindividual variability in drug response is a major clinical problem. Polymedication and
genetic polymorphisms modulating drug-metabolising enzyme activities (cytochromes P450 …

PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH OBSESSIVE-COMPULSIVE
DISORDER Page 1 Not for Distribution or Citation Draft 2, December 6, 2005 PRACTICE …

Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …

Of about one dozen human P450 s that catalyze biotransformations of xenobiotics, CYP2D6
is one of the more important ones based on the number of its drug substrates. It shows a …

The cytochrome P450 (CYP) enzymes are major players in drug metabolism. More than
2,000 mutations have been described, and certain single nucleotide polymorphisms (SNPs) …

Genetic factors contribute to the phenotype of drug response. We systematically analyzed all
available pharmacogenetic data from Medline databases (1970–2003) on the impact that …

Aim Comparative potency of proton-pump inhibitors (PPIs) is an important clinical issue.
Most available trials have compared the different PPIs at one or a few selected specific …